Testing effectiveness (Phase 2)WithdrawnNCT05496192
What this trial is testing
Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
Who this might be right for
MelanomaUrothelial Carcinoma
Bristol-Myers Squibb